Stellar Survival Data For AZ's Lynparza Hailed At ESMO

 
• By Kevin Grogan

Clinicians and analysts have lauded spectacular results presented at ESMO from the SOLO-1 trial which strongly suggest that AstraZeneca's Lynparza should be the first-line maintenance treatment of choice for ovarian cancer patients with a BRCA mutation.

Motorcycle
Lynparza leaps further ahead in the PARP class after SOLO-1 • Source: Shutterstock

More from Anticancer

More from Therapy Areas